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Abstract
 Background & Aims—Liver disease is the third leading cause of death in patients with cystic 
fibrosis (CF), but features of patients with CF, severe liver disease, and portal hypertension have 
not been fully characterized.
 Methods—We performed a retrospective analysis of data from 561 patients with CF (63% 
male, 99% with pancreatic insufficiency), liver disease (hepatic parenchymal abnormalities 
consistent with cirrhosis, confirmed by imaging), and portal hypertension (esophageal varices, 
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portosystemic collaterals, or splenomegaly), with no alternate causes of liver disease. All patients 
were enrolled in the Genetic Modifier Study of Severe CF Liver Disease at 76 international 
centers, from January 1999 through July 2013.
 Results—Male patients were diagnosed with liver disease at a younger age than female 
patients (10 vs 11 years; P=.01). Splenomegaly was observed in 99% of patients and varices in 
71%. Levels of liver enzymes were near normal in most patients. Thrombocytopenia affected 70% 
of patients and was more severe in patients with varices (88×109/L vs 145×109/L; P<.0001). 
Ninety-one patients received liver transplants (16%), at a median age of 13.9 years. Compared to 
patients who did not receive liver transplants, patients who received liver transplants had lower 
platelet counts (78×109/L vs 113×100/L; P<.0001), higher international normalized ratios (P<.
0001), and lower levels of albumin (P=.0002). The aminotransferase to platelet ratio index (APRi) 
and fibrosis index based on 4 factor (FIB-4) values were above diagnostic thresholds for CF liver 
disease in 96% and 90% of patients, respectively. Patients who received liver transplants or who 
had varices had higher APRi and FIB-4 values than patients who did not.
 Conclusions—In patients with CF, severe liver disease develops early in childhood (around 
10 years of age) and is more common in boys than girls. Patients with varices and those who 
receive liver transplants have more abnormal platelet counts and APRi and FIB-4 scores.
Keywords
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 Introduction
Cystic fibrosis (CF) is a life-limiting multisystem disease caused by mutations in both alleles 
of the CFTR gene. Liver disease is an independent risk factor for mortality1 and the third 
leading cause of death in CF, accounting for an overall mortality of 2.5%. The risk of 
developing cirrhosis (3-5%) is likely related to non-CFTR genetic variation and 
environmental influences2.
The non-specific term “CF-related liver disease” has been used to describe a spectrum of 
hepatobiliary diseases, ranging from neonatal cholestasis, liver biochemical changes, 
imaging abnormalities (e.g. liver parenchymal heterogeneity on ultrasound), and a variety of 
histological abnormalities (e.g. hepatic steatosis, cholestasis, and/or fibrosis), to severe liver 
disease characterized by cirrhosis with portal hypertension. In view of varying definitions 
previously used to report CF-related liver diseases, the phenotype of CF patients with 
cirrhosis and portal hypertension (i.e. severe CFLD) has not been properly characterized.
As part of our worldwide, multicenter study of genetic modifiers in CF, we carefully 
characterized the phenotype of the largest reported group of CF patients with severe liver 
disease with portal hypertension.
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 Methods
CFLD patients in this analysis were independently and specifically enrolled in the Genetic 
Modifier Study of Severe CF Liver Disease3 from 76 international CF centers between the 
14 year period from January, 1999, and July, 2013 (Figure 1).
Study enrollment required a CF diagnosis4, age ≥ 2 years, and diagnosis of CFLD confirmed 
by 1) imaging showing hepatic parenchymal abnormalities consistent with cirrhosis 
(including heterogeneous liver parenchyma), and 2) evidence of portal hypertension 
(including esophageal varices at endoscopy, portosystemic collaterals on imaging, or 
splenomegaly), and 3) absence of an alternative diagnosis for liver disease or portal 
hypertension. We excluded patients with prolonged use of parenteral nutrition in infancy (> 
2 months) and portal vein thrombosis without cirrhosis. For patients who underwent liver 
transplantation, clinical data were obtained prior to transplantation. Our diagnostic definition 
did not include liver biopsy since biopsies are not routinely performed in this population and 
the patchy nature of disease risks sampling error.
Data were independently reviewed by two physicians (P.R.D., S.C.L.) with CFLD expertise. 
Lack of agreement was resolved by discussion or with additional clinical data when 
necessary/available. Institutional review boards of all participating institutions approved this 
study.
The upper limit of normal (ULN) for males and females under 18 years old was 40 and 35 
IU/L for alanine aminotransferase (ALT), and for patients over 18 years old, 30 and 20 IU/L. 
ULN for gamma-glutamyl transferase (GGT) was ≤ 30 IU/L5-7. The aspartate 
aminotransferase (AST) to platelet ratio index (APRi) and fibrosis index based on four 
factors (FIB-4) were also calculated8-10.
Summary statistics, including counts with percentages, and medians with either range or 
25th and 75th percentiles, were computed. Fisher's exact test or Wilcoxon rank sum test were 
used. p value of < 0.05 was considered statistically significant.
 Results
Fifty-one of the 612 enrolled patients (8%) with a presumed diagnosis of CFLD were 
excluded (Figure 1); 32 due to an additional cause of liver disease or insufficient evidence 
of portal hypertension, 15 with incomplete clinical documentation, and 4 whose diagnosis of 
CFLD occurred > 30 years of age and therefore considered to be outliers.
We analyzed 561 patients from 76 CF centers in 24 countries (Figure 1, Table 1). 
Enrollment average age was 18.3 years (range 2.1 to 52.5 years), 63% male, and 94% 
Caucasian. Almost all CFLD patients were pancreatic insufficient (PI) (99%) and had two 
severe, loss-of function CFTR mutations (92%) (Table 1).
The median age of CFLD diagnosis was 10 years (Figure 2), 94% were diagnosed by 20 
years, 80% by 15 years, and 45% before 10 years old. Males with CFLD were diagnosed 
earlier than females (10.2 vs 11.4 years, p = 0.003) (Figure 2).
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Table 2 illustrates phenotypes and therapies in the CFLD patients. Varices were present in 
71% of the patients, of whom 85% had esophageal varices (35% of whom also had gastric 
varices) and 15% had only gastric varices. Males had documented varices earlier than 
females. Liver biopsy confirmed CFLD in 35% of patients, performed at a median of 4.8 
years before enrollment (range < 0.5 to > 20 years). Cholelithiasis was documented in 8% 
and distal intestinal obstruction syndrome (DIOS) in 26% of patients > 1 year old. 
Meconium ileus (MI) at birth occurred in both genders at similar rates (Table 2).
Most CFLD patients had liver enzyme concentrations in the normal to <2X ULN range 
(63%). GGT was more commonly elevated than ALT. Bilirubin concentrations were normal 
or <2X ULN in most patients (Table 3). Males had significantly higher median GGT, INR, 
and albumin concentrations than females (Table 3).
We calculated APRi and FIB-4 in 497 CFLD patients and found values differed by age and 
male gender, largely due to differences in AST (Table 4). APRi and FIB-4 scores exceeded 
the diagnostic thresholds reported by Leung et al. (APRi >0.264 and FIB-4 >0.358)10 in 
96% and 90% of our patients, respectively. Additionally, these biomarkers were significantly 
different in CFLD patients with and without known varices as well as those who have and 
have not undergone liver transplantation (Table 4).
Thrombocytopenia was common overall (70%), and more prevalent among patients with 
varices (78% vs 55%) whose platelet counts were significantly lower than those patients 
whose status of varices was unknown (median 88×109/L vs 145×109/L; p < 0.0001) (Table 
3). Patients with a transjugular intrahepatic portosystemic shunt (TIPS; n=40) were removed 
from analyses of platelet count to avoid confounding by shunt-induced changes to the 
platelet count. Patients with varices and also those undergoing liver transplantation were 
characterized by greater abnormalities in markers of disease severity (Tables 2 and 3).
Therapies for CFLD are summarized in Table 2. Among 91 liver transplant recipients 
(16%), there were no significant differences between gender and age in the proportion 
transplanted. Fifteen subjects (3%) underwent lung transplantation, 10 of whom underwent 
both lung and liver transplantation with eight patients having the transplants simultaneously 
(Table 2). Before transplantation, patients receiving a liver transplant had significantly lower 
platelet count (median platelet count 78×109/L vs 113×109/L; p < 0.0001) and were more 
likely to have elevated INR (INR >1.5 in 38% vs 12%, p < 0.0001) and lower albumin 
(albumin <3.5 g/dL in 60% vs 37%; p = 0.0002) compared to patients not undergoing liver 
transplantation (Table 3).
 Discussion
This worldwide study of 561 patients represents the largest reported cohort of CFLD 
patients enrolled according to a strict definition of severe disease and presents, for the first 
time, a rigorous and robust description of the characteristics of patients with severe CFLD 
with portal hypertension. The impact of liver disease on the health of patients with CF 
appears to be limited primarily to those with severe disease with portal hypertension. 
However, many published studies include a broader group of patients and do not adequately 
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distinguish descriptions of those with cirrhosis from those with milder disease. A clear 
understanding of the phenotype of severe CFLD enables comparison between patient 
cohorts and between different studies. Our description provides an important benchmark that 
is widely generalizable because it is derived from a large multi-national sample.
Key observations in this study include that severe CFLD: (a) arises early in life (median 10y) 
and new cases rarely appear in adulthood; (b) occurs in pancreatic insufficient patients 
(99%) or in patients who had two severe, loss-of function CFTR mutations (92%), which is 
considerably higher than the prevalence of pancreatic insufficient mutations in the general 
CF population (85%)11; (c) occurs in males more frequently than females (63% vs 37%); (d) 
is associated with normal or mildly elevated liver enzymes and liver function tests, and 
having an APRi >0.26410 and FIB-4 >0.35810 in the majority of patients, and (e) causes 
more severe abnormality in bloodwork markers of disease severity in those patients with 
varices and in those requiring liver transplantation (i.e. platelets, albumin, INR, and total 
bilirubin). Our findings are consistent with some previous reports based on smaller, single-
center studies of CF patients with varying definitions of liver disease that were not 
necessarily limited to cirrhosis and portal hypertension12,13.
Previous studies of MI in CFLD have shown conflicting results14, which may arise from the 
effects of small patient populations, varying definitions of MI (e.g. including meconium 
ileus “equivalent” or DIOS), and/or varying definitions of CF liver disease. The prevalence 
of MI in the global CF population is approximately 15-20%, but 17-22% in those with 
pancreatic insufficiency15. Nearly all of our CFLD patients have pancreatic insufficient CF 
and the incidence of MI in our patients is 22%, which is therefore not different from the 
appropriate control CF population without CFLD, suggesting that MI at birth does not 
increase the likelihood of severe CFLD. In addition, MI was not different when comparing 
patients with and without liver transplantation, nor those with or without known varices.
CFLD with portal hypertension affects males more commonly than females, even though it 
appears to develop before puberty in the majority of cases. Gender differences in prevalence 
or severity have also been described in primary sclerosing cholangitis, autoimmune hepatitis, 
viral hepatitis, non-alcoholic fatty liver disease, hepatocellular carcinoma, and primary 
biliary cirrhosis. Proposed explanations include differential exposure to environmental, 
hormonal, immune, and genetic factors. Gender differences have been demonstrated in 
hepatic gene expression16, hepatic function17, and immune function18. Studies have yet to 
explore these complex interactions in CFLD.
There was no pattern of liver enzyme abnormality that characterized these patients with 
severe CFLD or that would enable them to be readily differentiated from patients with 
milder variants of liver disease. Liver enzyme abnormalities are highly prevalent among all 
patients with CF, regardless of liver disease status19. Low platelet count was common in our 
cirrhotic CFLD patients and was more pronounced in those with varices and those 
undergoing transplantation, suggesting a role for this variable in diagnosis of severe CFLD 
and as a marker of disease severity. Future studies of platelet count changes in individual 
patients over time are awaited. Median INR was statistically significantly higher in patients 
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with varices and in those undergoing liver transplantation, but the absolute numerical 
differences were small and therefore of uncertain clinical usefulness.
The failure of standard blood tests and imaging to differentiate patients with CFLD 
highlights the need for the development of novel biomarkers for this important disease. 
Recent studies have tested the diagnostic accuracy of transient elastography, proteomic 
profiling, and a panel of circulating microRNAs20-22. The role of serum markers of 
fibrogenesis has also been studied23. These initial studies demonstrate that differences 
between established CF liver disease and CF patients with absence of liver disease can be 
shown. Based on a different definition of CFLD, APRi and FIB-4 were recently shown to 
predict CFLD with moderate sensitivity and specificity10. In nine of their CF patients with 
portal hypertension (which is the most comparable population to our 497 CF patients), they 
reported APRi and FIB-4 values of 0.96 and 0.76, respectively, compared to our median 
values of 1.15 and 1.16. Future studies may investigate the role of other non-invasive tests in 
CFLD, such as a “clinical prediction rule” (calculated from platelet count, spleen size z-
score, and albumin concentration) that is validated for the non-invasive diagnosis of children 
with esophageal varices24. There is a pressing need for further research in this area, 
particularly to identify markers that may predict children who will develop severe liver 
disease at an early time-point when preventative therapies may be effective.
The majority of CFLD patients in this study (89%) were receiving ursodeoxycholic acid, 
consistent with published recommendations25. Nonetheless, there is no evidence that this 
therapy positively modifies the clinical course of CFLD26 and the potential risk of adverse 
outcomes in patients with CFLD has not yet been adequately explored27,28. There remains a 
need for studies to elucidate the relative risks and benefits of ursodeoxycholic acid therapy 
for CFLD.
Sixteen percent of our patients have undergone liver transplantation. In general, among 
patients with CFLD severe enough to be listed for liver transplantation, there is a survival 
benefit for patients who achieve transplant29. Although criteria for listing for liver 
transplantation for CFLD have been suggested25, it is often challenging to determine the 
optimal timing of liver transplantation in cirrhotic CFLD patients. It is hoped that future 
prospective studies may help to further clarify the indications and optimal timing of liver 
transplantation for severe CFLD.
Our study is the largest population of well-phenotyped CF patients with portal hypertension 
due to cirrhosis. The limitations of this study include the lack of availability of requested 
data for some subjects, and lack of assessment of differences in clinical practice among the 
76 CF centers (e.g. dose of ursodeoxycholic acid, indications for endoscopy, liver biopsy, 
and liver transplantation). We were not able to measure the prevalence of disease due to the 
wide variation between enrolling centers in their referral patterns and ability to accurately 
characterize the population of CF patients that they serve. Longitudinal data in individual 
patients was not collected. However, recruitment of subjects worldwide ensures 
generalizability of our findings across all CF populations.
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In summary, our international collaboration has successfully compiled and described the 
clinical characteristics of the largest reported group of adults and children with severe 
CFLD. We have confirmed that this disease presents early in childhood, males are more 
likely to be affected, liver enzymes are usually normal or near-normal, and nearly all have 
pancreatic insufficiency. Patients with varices, as well as those who require liver 
transplantation, are characterized by greater abnormalities of platelet count, albumin, INR, 
total bilirubin, APRi and FIB-4. Further studies with this group of patients are underway, 
aiming to define further genetic risk factors and pathways to help our understanding of 
disease pathogenesis and to identify potential therapeutic targets.
 Supplementary Material
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 List of abbreviations
ALT alanine transferase
APRi aspartate aminotransferase to platelet ratio index
AST aspartate aminotransferase
CF cystic fibrosis
CFLD cystic fibrosis liver disease
DIOS distal intestinal obstruction syndrome
FIB-4 fibrosis index based on 4 factors
GGT gamma-glutamyl transferase
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INR international normalized ratio
IU/L international units per liter
MI meconium ileus
PI pancreatic insufficient
TIPS transjugular intrahepatic portosystemic shunt
ULN upper limit of normal
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Fig. 1. Patients enrolled in the Genetic Modifier Study of CF Liver Disease (CFLD Study) from 
January, 1999 up to July 2013, by age and gender
Those who were confirmed with severe CFLD and diagnosed after 30 years (n=4) were four 
or more standard deviations above the mean of the normal distribution, which more likely 
reflects an environmental insult, and therefore were not included in the analysis.
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Fig. 2. Age of liver disease diagnosis in CFLD subjects by gender
Age distribution of diagnosis of liver disease (portal hypertension) in patients with 
confirmed CFLD and a reported year of CFLD diagnosis (n=515). Males in white bars and 
females overlapped in black bars.
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Table 1
Demographics and characteristics in CFLD patients
Description All n =561 Malesa n =353 (63%) Females n =208 (37%)
Age (years) at enrollment, mean (±SD) 18.3 (±7.2) 18.1 (±6.8) 18.7 (±7.8)
    Median (range) 17.4 (2.1-52.5) 17.2 (2.8-44.8) 17.9 (2.1-52.5)
Race, n (%)
    Caucasian 529 (94) 334 (95) 195 (94)
    Hispanic 16 (3) 8 (2) 8 (4)
    African American 4 (1) 2 (1) 2 (1)
    Other 12 (2) 9 (2) 3 (1)
Enrollment by continent, n (%)
    North America 273 (49) 166 (47) 107 (52)
    Europe 242 (43) 158 (45) 84 (40)
    Australia 25 (5) 17 (5) 8 (4)
    Asia 13 (2) 8 (2) 5 (2)
    South America 8 (1) 4 (1) 4 (2)
Pancreatic status, n (%)
    Pancreatic insufficient (PI) 556 (99) 351 (99) 205 (99)
    Pancreatic sufficient (PS) 5 (1) 2 (1) 3 (1)
PI/PS genotype based on CFTR alleles, n (%)
    PI/PI 514 (92) 324 (92) 190 (92)
    PI/PS 11 (2) 6 (2) 5 (2)
    PI/Unknown 28 (5) 20 (5) 8 (4)
    Unknown/unknown 8 (1) 3 (1) 5 (2)
Pancreatic insufficiency prevalence, n (%) n =486 n =311 n =175
    0.75 – 1.0 (severe) 473 (97) 303 (97) 170 (97)
    0.25 – < 0.75 (moderate) 12 (2) 8 (3) 4 (2)
    < 0.25 (mild) 1 (1) 0 (0) 1 (1)
CFTR genotype available, n (%) n =525 n =330 n =195
    Phe508del/Phe508del 298 (57) 196 (59) 102 (52)
    Phe508del/Other 183 (35) 106 (32) 77 (40)
    Other/Other 44 (8) 28 (9) 16 (8)
b
 Pancreatic insufficiency prevalence (PIP) score developed and validated by Ooi and Durie11.
aCFLD occurs in males more frequently than females (p = 0.0006).
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Table 4
Liver-related biomarkers/ratios by gender, age, and phenotype in CFLD patients
Description n APRia FIB-4b Agec, years Platelets, ×10
9/L AST, IU/L ALT, IU/L
All CFLD Patients
All 497 1.15 (0.66, 2.05) 1.16 (0.61, 2.04) 16.1 (12.3, 21.2) 101 (63, 161) 45 (31, 67) 41 (28, 68)
Male 310 1.23 (0.68, 2.18) 1.25 (0.63, 2.22) 16.0 (12.1, 20.5) 98 (61, 157) 47 (32, 69) 44 (30, 72)
Female 187 1.05 (0.63, 1.73) 1.06 (0.61, 1.92) 16.9 (12.4, 21.8) 110 (67, 166) 41 (30, 62) 38 (26, 56)
p valued 0.038 0.308 0.155 0.295 0.029 0.011e
Age < 18 years
All 302 1.25 (0.74, 2.10) 1.01 (0.49, 1.74) 13.1 (10.5, 15.6) 103 (69, 160) 48 (37, 73) 43 (31, 71)
Male 197 1.34 (0.74, 2.23) 1.08 (0.54, 1.78) 13.2 (10.4, 15.7) 103 (65, 153) 49 (38, 78) 46 (30, 73)
Female 105 1.16 (0.75, 1.77) 0.80 (0.43, 1.56) 12.9 (10.8, 15.6) 102 (72, 174) 47 (36, 66) 41 (32, 64)
p valued 0.102 0.108 0.774 0.416 0.169 0.353
Age ≥ 18 years
All 195 0.99 (0.58,1.99) 1.56, (0.83, 2.78) 22.5 (19.9, 26.0) 100 (58, 164) 36 (27, 57) 39 (24. 62)
Male 113 1.05 (0.58, 2.04) 1.62 (0.79, 2.91) 22.4 (19.6, 25.8) 90 (56, 167) 39 (27, 58) 43 (29, 68)
Female 82 0.88 (0.55, 1.56) 1.40 (0.85, 2.37) 22.7 (20.2, 26.3) 113 (63, 160) 34 (26, 53) 36 (21, 51)
p valued 0.329 0.658 0.489 0.523 0.213 0.010e
p value by agef
All 0.004 <0.0001 not applicable 0.409 <0.0001 0.007e
Male 0.031 0.0001 not applicable 0.411 <0.0001 0.264
Female 0.078 <0.0001 not applicable 0.632 0.0002 0.006e
Known varices
No varices 139 0.90 (0.48, 1.48) 0.70 (0.41, 1.26) 15.3 (11.2, 19.3) 145 (87, 198) 45 (31, 65) 46 (31, 70)
Varices 335 1.27 (0.72, 2.29) 1.47 (0.81, 2.47) 17.6 (13.7, 22.2) 88 (56, 142) 44 (31, 65) 41 (27, 66)
p valued <0.0001 <0.0001 0.001 <0.0001 0.691 0.100
Liver transplant
No transplant 422 1.06 (0.62, 1.99) 1.05 (0.57, 1.87) 17.0 (12.7, 21.4) 113 (70, 171) 45 (31, 65) 42 (29, 69)
Transplant 68 1.59 (1.11, 2.69) 1.96 (1.18, 3.25) 13.3 (10.2, 17.1) 78 (54, 99) 45 (32, 72) 38 (27, 59)
p valued 0.0001 <0.0001 0.0005 <0.0001 0.549 0.349
p values (<0.05 shown in bold) generated using Wilcoxon rank sum test (for medians).
Data presented as median (25th and 75th percentiles).
aAPRi = (AST [IU/L]/ULN AST*100)/platelet count [109/L]. ULN for AST was 40 IU/L.
b
FIB-4 = (Age [years] * AST [IU/L])/(platelet count [109L] * square root ALT [IU/L]).
cAge, in years = age at blood test.
dp value comparing males vs. females
e
The apparent difference between genders is clinically non-significant due to different upper limit of number (ULN) in ALT for males and females.
fp value by age comparing patients with blood tests performed < 18 vs. ≥ 18 years of age.
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